Such tumor suppressor properties of FOXO1 in human BCs are also in agreement with our recent findings that downregulation of FOXO1 expression promotes BC invasion abilities (G.J., unpublished data) and that the anti-cancer compound isorhapontigenin is able to elevate FOXO1 expression and inhibit invasion of human BC cells,42 suggesting that inhibition of FOXO1 might be of therapeutic benefit for human BC patients. Here, FOXO1 is linked to neoplasm.